LOGO VASCULITIS fecha
BANNER GESCO 128kb

@VasculitisBCN24

Full programme


  • SUNDAY, APRIL 7TH
    Room Plenary room (Room 112) Poster Area
    13:00 - 19:00 Registration
    15:00 - 15:30 WELCOME
     
    15:30 - 16: 30 FOKKO VAN DER WOUDE LECTURE
    The evolving landscape of vasculitis management: past, current, and emerging therapies
     
    16:30 - 16:45 COFFEE BREAK
    16:45 - 17:45   POSTER TOUR 1
    17:45 - 18:45 PLENARY SESSION
    Innovative approaches for vasculitis researchers.
     
    SUNDAY, 7 APRIL | 15:00-15:30 | ROOM 112
    Add to calendar 2024-04-07 15:00 2024-04-07 15:30 Europe/Madrid WELCOME VASCULITIS 2024
     
    WELCOME

    Welcome by María C Cid (Co-chair) on behalf of the Organizing Committee
    Welcome by Georgina Espigol Frigolé (Co-chair)
    Welcome by Michela Bertero (IDIBAPS Strategy Director)
    Welcome by Davide Malmusi (Director of Health Services, Barcelona)
    Closing speech and introduction to the Plenary Session

    SUNDAY, 7 APRIL | 15:30-16:30 | ROOM 112
    Add to calendar 2024-04-07 15:30 2024-04-07 16:30 Europe/Madrid FOKKO VAN DER WOUDE LECTURE VASCULITIS 2024
     
    FOKKO VAN DER WOUDE LECTURE

    Chairs:
    Luis Felipe Flores Suarez. Primary Systemic Vasculitides Clinic. Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
    David Jayne. University of Cambridge, Cambridge, United Kingdom.

    The evolving landscape of vasculitis management: past, current, and emerging therapies
    Speaker: Ronald Falk. University of North Carolina, Chapel Hill, NC, United States.

    SUNDAY, 7 APRIL | 17:45-18:45 | ROOM 112
    Add to calendar 2024-04-07 17:45 2024-04-07 18:45 Europe/Madrid PLENARY SESSION - INNOVATIVE APPROACHES FOR VASCULITIS RESEARCHERS VASCULITIS 2024
     
    PLENARY SESSION - INNOVATIVE APPROACHES FOR VASCULITIS RESEARCHERS

    Chairs:
    Alan Salama. University College London, London, United Kingdom.
    Richard Kitching. Monash University and Monash Health, Melbourne, Australia.

    Lecture: How immune/inflammatory cell atlas contribute to research in immune-mediated diseases?
    Speaker: Juan C Nieto. National Center for Genomic Analysis (CNAG), Barcelona, Spain

    Lecture: Kidney organoids: from development to human diseases.
    Speaker: Nuria Montserrat. Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain

    SUNDAY, 7 APRIL | 16:45-17:45 | POSTER AREA
    Add to calendar 2024-04-07 16:45 2024-04-07 17:45 Europe/Madrid POSTER TOUR 1 VASCULITIS 2024
     
    POSTER TOUR 1

    1A: ADVANCES IN TREATMENT
    Chair: Rona Smith. University of Cambridge, Cambridge, United Kingdom

    • PT-1A-01. Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients With ANCA-Associated Vasculitis
      Speaker: Benjamin Terrier. Cochin Hospital, Paris, France
    • PT-1A-02. Characterizing Treatment Response, Tolerability, and Rationale for Choosing Avacopan Therapy in Patients with ANCA-Associated Vasculitis: A Multicenter Observational Study in a Real-World Setting
      Speaker: Jonas Zimmermann. Charité - Universitätsmedizin, Berlin, Germany
    • PT-1A-03. Infections during the avacopan early access program (EAP) for anca-associated vasculitis (AAV)
      Speaker: Javier Villacorta. Hospital Ramon y Cajal, Madrid, Spain
    • PT-1A-04. Avacopan in the treatment of ANCA-associated Vasculitis with Hypoxic Pulmonary Haemorrhage
      Speaker: Aglaia Chalkia. University of Cambridge, Cambridge, United Kingdom
    • PT-1A-05. Avacopan for the treatment of ANCA Vasculitis. First experiences in Spain
      Speaker: Juliana Bordignon Draibe. Hospital Universitari de Bellvitge, Barcelona, Spain
    • PT-1A-06. Real-world experience comparing Avacopan use to high dose steroids as part of remission induction therapy in ANCA-associated vasculitis
      Speaker: Catherine King. University of Birmingham, Edgbaston, United Kingdom
    • PT-1A-07. Efficacy and Safety Experience with Avacopan beyond 52 weeks in Early Access Program (EAP)
      Speaker: Tamara Popov. CSL Vifor, Glattbrugg, Switzerland
    • PT-1A-08. Efficacy and safety of combination therapy with rituximab and low-dose cyclophosphamide in ANCA-associated renal vasculitis
      Speaker: María Maldonado. H. Universitario La Paz, Madrid, Spain
    • PT-1A-09. Timing B cell Return for Maintenance Rituximab
      Speaker: Gabriel Sauvage. Mass General Hospital, Boston, United States
    • PT-1A-10. Rituximab vs. Combination of Rituximab and Cyclophosphamide Induction Therapy for ANCA-associated vasculitis: A retrospective study
      Speaker: Katja Von Allwörden. University of Lübeck, Lübeck, Germany


    1B: OUTCOMES AND PREDICTORS
    Chair:
    Neil Basu. University of Glasgow, Glasgow, United Kingdom

    • PT-1B-32. The 2022 ACR/EULAR classification criteria for Takayasu arteritis predict mortality better than the 1990 ACR classification criteria: a cohort study
      Speaker: Durga Prasanna Misra. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
    • PT-1B-33. Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
      Speaker: Tanaz Kermani. University of California Los Angeles, Los Angeles, California, United States
    • PT-1B-34. Age, Hypertension and Anticoagulant Therapy at Presentation are Associated with Cranial Ischaemic Complications in Giant Cell Arteritis
      Speaker: Njm Chaddock. School of Medicine, University of Leeds and NIHR Leeds BRC, LTHT, Leeds, United Kingdom
    • PT-1B-35. Presentation and outcome of silent giant cell arteritis: a retrospective cohort study
      Speaker: Lien Moreel. UZ Leuven and KU Leuven, Leuven, Belgium
    • PT-1B-36. Five-year analysis of patient reported outcomes in a longitudinal cohort of giant cell arteritis and polymyalgia rheumatica patients
      Speaker: Yannick Van Sleen. University Medical Center Groningen, Groningen, Netherlands
    • PT-1B-36. Five-year analysis of patient reported outcomes in a longitudinal cohort of giant cell arteritis and polymyalgia rheumatica patients
      Speaker: Yannick Van Sleen. University Medical Center Groningen, Groningen, Netherlands
    • PT-1B-37. Imaging to predict relapses after treatment discontinuation in patients with large vessel giant cell arteritis – a cohort study
      Speaker: Andrea Hemmig. University Hospital Basel, Basel, Switzerland
    • PT-1B-38. Patients experiences of Polymyalgia Rheumatica: A Qualitative Literature Synthesis Review
      Speaker: Max Yates. Norwich Medical School, University of East Anglia, Norwich, United Kingdom
    • PT-1B-39. Relapses in large vessel vasculitis occur in a different arterial territory as compared to diagnosis
      Speaker: Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
    • PT-1B-40. Polymyalgia rheumatica is a risk factor for more recalcitrant disease in giant cell arteritis: a retrospective cohort study
      Speaker: Lien Moreel. UZ Leuven and KU Leuven, Leuven, Belgium
    • PT-1B-41. Severe ischemic events in Takayasu’s Arteritis –A multi-national retrospective study
      Speaker: Gozde Kubra Yardımcı. Vasculitis Clinic, Mount Sinai Hospital, Toronto, Canada


    1C: MECHANISMS OF DISEASE
    Chair:
    Peter Heeringa. University Medical Center Groningen, Groningen, The Netherlands

    • PT-1C-63. Complement activation in anti-GBM disease before and after treatment with imlifidase
      Speaker: Linnéa Tyrberg. Lund University and Helsingborg Hospital, Lund; Helsingborg, Sweden
    • PT-1C-64. Increased miRNA-184 expression is linked to inflammatory cell death in Granulomatosis with Polyangiitis
      Speaker: Anja Staehle. University of Luebeck, Luebeck, Germany
    • PT-1C-65. Identification of Antibodies against Peroxidasin in Human and Experimental Glomerulonephritis
      Speaker: Lyndon Costa. Imperial College London, London, United Kingdom
    • PT-1C-66. Comparative analysis of phenotypic and functional properties of LDNs in AAV, sepsis and lung cancer patients
      Speaker: Amrita Dwivedi. Trinity College Dublin, Dublin, Republic of Ireland
    • PT-1C-67. FTY720 ameliorates experimental MPO-ANCA-associated vasculitis by regulating fatty acid oxidation via the neutrophil PPARα-CPT1a pathway
      Speaker: Zhi-Ying Li. Peking University First Hospital, Beijing, China
    • PT-1C-68. Dynamic alterations of non-classical and intermediate monocytes in patients with ANCA vasculitis
      Speaker: Dominic Ciavatta. University of North Carolina at Chapel Hill, Chapel Hill, United States
    • PT-1C-69. PD-1, PD-L1 and PD-L2: performance of immune checkpoint molecules in ANCA vasculitis
      Speaker: Paula Anton Pampols. Department of Nephrology, Bellvitge University Hospital., Hospitalet de Llobregat, Spain
    • PT-1C-70. Overlapping macrophage profiles in PMR bursa and GCA temporal artery biopsies
      Speaker: Anqi Zhang. University Medical Center Groningen, Groningen, Netherlands
    • PT-1C-71. A macrophage-smooth muscle cells axis directs vascular remodeling via the activation of the EGFR pathway in giant cell arteritis
      Speaker: Kevin Chevalier. Cochin Hospital - Assistance Publique Hôpitaux de Paris, Paris, France
    • PT-1C-72. Investigation of systemic Interferon type I responses in patients with giant cell arteritis and polymyalgia rheumatica
      Speaker: Marieke Van Nieuwland. Hospital Group Twente, Almelo, Netherlands

  • MONDAY, APRIL 8TH
    Room Plenary room (Room 112) Room 113 Room 118+119 Poster Area
    07:00 - 18:40 Registration
    08:00 - 09:45 PLENARY SESSION
    Cellular and molecular mechanisms of disease.
         
    09:45 - 10:30 COFFEE BREAK POSTER TOUR 2
    10:30 - 12:30 PLENARY SESSION
    Advances in treatment (I)
         
    12:30 - 13:30   INDUSTRY SYMPOSIUM    
    LUNCH BREAK
    13:30 - 15:00 BREAKOUT SESSION
    Genetic and environment conditionings of vasculitis
    BREAKOUT SESSION
    Transcriptomic approaches to the study of systemic vasculitis
    BREAKOUT SESSION
    Management of specific situations
     
    15:00 - 16:20 BREAKOUT SESSION
    Biomarkers of clinical interest.
    BREAKOUT SESSION
    Advances in polymyalgia rheumatica
    BREAKOUT SESSION
    Optimizing new treatments
     
    16:20 - 16:40 COFFEE BREAK
    16:40 - 17:40 DEBATE
    Should glucocorticoid discontinuation as in clinical trials be a therapeutic target in real life?
    DEBATE
    Does plasma exchange have a role in ANCA-associated vasculitis?
    SMALL WORKSHOP
    Choosing adjuvant therapy (conventional or targeted) in Takayasu arteritis
     
    17:40 - 18:40 CASE REPORT AND PANEL DISCUSSION
    DEBATE
    Should tocilizumab be used in every patient with giant-cell arteritis?
    SMALL WORKSHOP
    Differences in guidelines (ACR/EULAR/KADIGO/CANVASC/Japanese) for the treatment of AAV: implications for clinical practice
     
    MONDAY, 8 APRIL | 08:00-09:45 | ROOM 112
    Add to calendar 2024-04-08 08:00 2024-04-08 09:45 Europe/Madrid PLENARY SESSION | CELLULAR AND MOLECULAR MECHANISMS OF DISEASE VASCULITIS 2024
     
    PLENARY SESSION
    CELLULAR AND MOLECULAR MECHANISMS OF DISEASE

    Chairs
    Peter Heeringa. University Medical Center Groningen, Groningen, The Netherlands
    Adrian Schreiber. Charité - Universitätsmedizin, Berlin, Berlin, Germany

    O-001. Regulatory T Cells Contribute to Downregulation of the Autoimmune Anti-MPO Response.
    Speaker: Meghan Free. UNC-Chapel Hill, Chapel Hill, United States

    O-002. Manipulation of the gut microbiome protects from kidney inflammation and injury in experimental myeloperoxidase anti neutrophil cytoplasmic antibody vasculitis.
    Speaker: Kim Maree O'Sullivan. Monash University, Melbourne, Australia

    O-003. Myeloperoxidase-specific IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Speaker: Diane Van Der Woude. Leiden University Medical Center, Leiden, Netherlands

    O-004. CD19 CAR T cells mediate nephroprotective effects in a murine model of ANCA-induced crescentic glomerulonephritis.
    Speaker: Dörte Lodka. Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

    O-005. Effect of interleukin-17 in giant cell arteritis.
    Speaker:
    Maxime Samson. Dijon University Hospital; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Dijon, France

    O-006. Type I interferon pathway is upregulated in microscopic polyangiitis (vs granulomatosis with polyangiitis).
    Speaker: Benoit Brilland. CHU Angers, Angers, France

    O-007. DNA repair antibody Deoxy Mab 1 inhibits neutrophil extracellular traps (NETs) and attenuates inflammation and kidney injury in experimental anti neutrophil cytoplasmic antibody vasculitis
    Speaker:
    Kim Maree O'Sullivan. Monash University, Melbourne, Australia

    MONDAY, 8 APRIL | 10:30-12:30 | ROOM 112
    Add to calendar 2024-04-08 10:30 2024-04-08 12:30 Europe/Madrid PLENARY SESSION | ADVANCES IN TREATMENT (I) VASCULITIS 2024
     
    PLENARY SESSION
    ADVANCES IN TREATMENT (I)

    Chairs
    Rona Smith. University of Cambridge, Cambridge, United Kingdom
    Bernhard Hellmich. University of Tübingen, Kirchheim-Teck, Germany

    O-008. A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis.
    Speaker: Carol Langford. Cleveland Clinic, Cleveland, United States

    O-009. A multicenter, randomized, controlled trial evaluating the effects of low-dose glucocorticoids compared to stopping glucocorticoids to maintain remission of granulomatosis with polyangiitis: The TAPIR trial.
    Speaker: Peter Merkel. University of Pennsylvania, Philadelphia, United States

    O-010. The effect of plasma exchange on early renal improvement in patients with ANCA-associated vasculitis: a post-hoc analysis of the PEXIVAS trial.
    Speaker: Balazs Odler. Medical University of Graz, Graz, Austria

    O-011. Innovative anti-pneumococcal vaccine strategies versus standard vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
    Speaker: Benjamin Terrier. Cochin Hospital, Paris, France

    O-012. Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
    Speaker: Peter Merkel. University of Pennsylvania, Philadelphia, United States

    O-013. Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis?
    Speaker: Ulrich Specks. Mayo Clinic, Rochester, United States

    Lecture: Emerging cell therapies in the vasculitis field
    Speaker: Meghan Free. UNC-Chapel Hill, Chapel Hill, United States

    MONDAY, 8 APRIL | 09:45-10:30 | POSTER & EXHIBITION AREA
    Add to calendar 2024-04-08 09:45 2024-04-08 10:30 Europe/Madrid COFFEE BREAK & POSTER TOUR 2 VASCULITIS 2024
     
    COFFEE BREAK & POSTER TOUR 2

    2A: ADVANCES IN TREATMENT
    Chair: Kenneth Warrington. Mayo Clinic, Rochester, United States

    • PT-2A-11. Differences between glucocorticoids, conventional DMARDs and tocilizumab in achieving disease remission and in preventing the progression of damage in giant cell arteritis patients
      Speaker: Federica Davanzo. University of Padova, Padova, Italy
    • PT-2A-12. Effectiveness of conventional and biologic DMARDs in treatment of non-infectious aortitis
      Speaker: Shirish Dubey. Oxford University Hospitals NHS FT, Oxford, United Kingdom
    • PT-2A-13. Clinical description and associated treatment in 78 patients with Takayasu's arteritis: results from the Spanish Registry of Systemic Vasculitis (REVAS)
      Speaker: Jaume Mestre-Torres. Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain
    • PT-2A-14. Safety and efficacy of long-term treatment with Tocilizumab in a cohort of patients affected by Giant Cell Arteritis: an Italian monocentric retrospective study
      Speaker: Riccardo Terribili. Siena University Hospital, Siena, Italy
    • PT-2A-15. Treatment of Giant Cell Arteritis with Ultra-short Glucocorticoids and Tocilizumab: results from the extension to 76 weeks
      Speaker: Chiara Marvisi. Azienda Unità Sanitaria Locale-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
    • PT-2A-16. Risk of major adverse cardiac events among patients with giant cell arteritis who received tocilizumab
      Speaker: Michael Putman. Medical College of Wisconsin, Milwaukee , United States
    • PT-2A-17. Outcomes of Vascular Intervention in Takayasu Arteritis Patients: A Tertiary Centre Experience From Turkey 
      Speaker: Fatma Alibaz-Oner. Marmara University, Istanbul, Turkey


    2B: OUTCOMES AND PREDICTORS
    Chair:
    Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

    • PT-2B-42. Identification of ANCA associated vasculitis relapse risk factors for building model for personalized maintenance therapy scheme
      Speaker: Krzysztof Wójcik. Jagiellonian University Medical College, Kraków, Poland
    • PT-2B-43. Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
      Speaker: Lisa Uchida. University of Cambridge, Cambridge, United Kingdom
    • PT-2B-44. Is there any advantages of the use of the Glucocorticoid Toxicity Index among the patients with vasculitis?
      Speaker: Omer Karadag. Hacettepe University Vasculitis Research Centre, Ankara, Turkey
    • PT-2B-45. Clinical presentations and outcomes in seronegative versus seropositive ANCA associated glomerulonephritis - An international cohort study
      Speaker: Lauren Floyd. Royal Preston Hospital, Preston, United Kingdom
    • PT-2B-46. Influence of histological tempol artery biopsy findings on outcomes of biopsy-proven giant cell arteritis in Italian patients : a long single center follow-up study
      Speaker: Luigi Boiardi. ASMN IRCCS REGGIO EMILIA, Reggio Emilia, Italy
    • PT-2B-47. Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study
      Speaker: Adrien Cottu. Cochin Hospital, Paris, France
    • PT-2B-48. ANCA vasculitis with renal involvement. Is age an issue?
      Speaker: Andrea Cifuentes-Talavera. Hospital Universitario 12 de Octubre, Madrid, Spain


    2C: MECHANISMS OF DISEASE
    Chair:
    Alan Salama. University College London, London, United Kingdom

    • PT-2C-73. A novel cathepsin C inhibitor suppressed development of MPO-ANCA-associated vasculitis in rat model
      Speaker: Yuka Nishibata. Hokkaido University, Sapporo, Japan
    • PT-2C-74. Expansion of TCRβ clonotypes contributing to recognition of viral peptides in nasal tissue indicates active granulomatosis with polyangiitis
      Speaker: Antje Müller. University of Lübeck, Luebeck, Germany
    • PT-2C-75. Phenotypic and functional alteration of unconventional T cells in adult IgA vasculitis
      Speaker: Antoine Hankard. Centre D'Étude des Pathologies Respiratoires, Tours, France
    • PT-2C-76. ANCA induced changes in neutrophil cytoskeleton and biomechanics are modulated by hypoxia, and associate with disease phenotype in AAV
      Speaker: N Pisacano. Imperial College London, London, United Kingdom
    • PT-2C-77. Activation of endothelial cells and priming of circulating PMN by high serum IgA are required to elicit IgA vasculitis
      Speaker: Cord Sunderkötter. University Hospital Halle, Halle, Germany
    • PT-2C-78. Exploring Biological Ageing in ANCA-Associated Vasculitis
      Speaker: Jordy Smith. Trinity College Dublin, Dublin, Republic of Ireland
    • PT-2C-79. Cytomegalovirus reactivation and renal damage in active ANCA-associated vasculitis
      Speaker: Catherine King. University of Birmingham, Edgbaston, United Kingdom

    MONDAY, 8 APRIL | 13:30-15:00 | ROOM 112
    Add to calendar 2024-04-08 13:30 2024-04-08 15:00 Europe/Madrid BREAKOUT SESSION | GENETIC AND ENVIRONMENT CONDITIONINGS OF VASCULITIS VASCULITIS 2024
     
    BREAKOUT SESSION
    GENETIC AND ENVIRONMENT CONDITIONINGS OF VASCULITIS

    Chairs:
    Neil Basu. University of Glasgow, Glasgow, United Kingdom.
    Peter Grayson. National Institutes of Health, Bethesda, United States

    Lecture: Potential climate determinants of different types of vasculitis.
    Speaker: Xavier Rodo. Climate and Health Program, ISGlobal, Barcelona, Spain

    O-014. Association between infections and the onset of giant-cell arteritis and polymyalgia rheumatica: a nested case control Study from the French E3N-EPIC cohort study
    Speaker
    : Lucas Pacoureau. Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France

    O-015. Genetic susceptibility to patterns of arterial involvement in Takayasu arteritis
    Speaker: Amr H. Sawalha. University of Pittsburgh, Pittsburgh, United States

    O-016. A large-scale genome-wide association study of polymyalgia rheumatica to identify disease-specific loci
    Speaker: Dimitria-Ilektra Lerou. University of Leeds, UK, Leeds, United Kingdom

    O-017. HLA in ANCA-associated vasculitis: thorough characterization of genetic associations in a Scandinavian cohort
    Speaker: Johanna Dahlqvist. Uppsala University, Uppsala, Sweden

    MONDAY, 8 APRIL | 13:30-15:00 | ROOM 113
    Add to calendar 2024-04-08 13:30 2024-04-08 15:00 Europe/Madrid BREAKOUT SESSION | GENETIC AND ENVIRONMENT CONDITIONINGS OF VASCULITIS VASCULITIS 2024
     
    BREAKOUT SESSION
    TRANSCRIPTOMIC APPROACHES TO THE STUDY OF SYSTEMIC VASCULITIS

    Chairs:
    Ann Morgan. University of Leeds, Leeds, United Kingdom
    Dominic Ciavatta. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

    Lecture: Spatial transcriptomics in glomerular diseases
    Speaker: Renate Kain. Medical University Vienna, Vienna, Austria

    O-018. Multi-level transcriptomic profiling of temporal artery tissue reveals novel pathways involved in the immune process and vascular remodelling in giant cell arteritis.
    Speaker: Michael Zulcinski. University of Leeds, Leeds, United Kingdom

    O-019. Single-cell RNA-sequencing exposes biological differences in giant cell arteritis lesions between disease relapse and disease onset
    Speaker:
    Maira Karabayas. University of Aberdeen, Aberdeen, United Kingdom

    O-020. Genes deregulated in giant cell arteritis by high-throughput expression profiling in temporal artery biopsies
    Speaker: Stefania Croci. AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    O-021. Single-cell multi-omics unveils increased activation of the IL-6/STAT3/PIM1 axis in T cell subsets of granulomatosis with polyangiitis patients
    Speaker: Nanthicha Inrueangsri. University Medical Center Groningen, Groningen, The Netherlands

    MONDAY, 8 APRIL | 13:30-15:00 | ROOM 118 + 119
    Add to calendar 2024-04-08 13:30 2024-04-08 15:00 Europe/Madrid BREAKOUT SESSION | MANAGEMENT OF SPECIAL SITUATIONS VASCULITIS 2024
     
    BREAKOUT SESSION
    MANAGEMENT OF SPECIAL SITUATIONS

    Chairs:
    Ahmet Gul. Istanbul University, Istanbul, Turkey
    Carol Langford. Cleveland Clinic, Cleveland, United States.

    O-022. Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
    Speaker: Gulen Hatemi. Istanbul University-Cerrahpasa,, Istanbul, Turkey

    O-023. Reproductive Outcomes for Women with Vasculitis
    Speaker: Catherine Sims. Duke University, Durham, United States

    O-024. Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry
    Speaker: Catherine Sims. Duke University, Durham, United States

    O-025. Evaluating the role of immunosuppression in ANCA+ve and idiopathic subglottic stenosis
    Speaker: Guy Benshetrit. Imperial College London, London, United

    O-026. Subglottic stenosis in patients with granulomatosis with polyangiitis – the clinical value of an airway biopsy
    Speaker: Louise Linde. RIGSHOSPITALET, Copenhagen, Denmark

    O-027. An Updated Cohort of Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
    Speaker: Samuel Falde. Mayo Clinic, Rochester, United States

    MONDAY, 8 APRIL | 15:00-16:20 | ROOM 112
    Add to calendar 2024-04-08 15:00 2024-04-08 16:20 Europe/Madrid BREAKOUT SESSION | BIOMARKERS OF CLINICAL INTEREST VASCULITIS 2024
     
    BREAKOUT SESSION
    BIOMARKERS OF CLINICAL INTEREST

    Chairs:
    Mark Little. Trinity College Dublin, Dublin, Ireland
    Elizabeth Brouwer. University Medical Center Groningen, Groningen, The Netherlands

    O-028. Autoantibody profiling to identify novel candidate biomarkers in ANCA associated vasculitis
    Speaker: Elisa Pin. KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden

    O-029. Torque teno virus as a potential biomarker for assessment of immunocompetence in patients with ANCA-associated vasculitis
    Speaker: Balasz Odler. Medical University of Graz, Graz, Austria

    O-030. A germline genetic biomarker predicts treatment response to tocilizumab in giant cell arteritis
    Speaker: Peter Grayson. National Institutes of Health, Bethesda, United State

    O-031. Serial measures of usCD163 predict kidney failure in AAV-GN
    Speaker: Sinead Stoneman. University College Cork, Cork, Republic of Ireland

    O-032. Plasma and urine metabolomic profiles reveal potential biomarkers in MPO-ANCA-GN
    Speaker: Yong Zhong. Xiangya Hospital, Central South University, Changsha, China

    O-033. Circulating Immune Profile in Granulomatosis with Polyangiitis Reveals Distinct Patterns Related to Disease Activity
    Speaker: Nanthicha Inrueangsri. University Medical Center Groningen, Groningen, Netherlands

    MONDAY, 8 APRIL | 15:00-16:20 | ROOM 113
    Add to calendar 2024-04-08 15:00 2024-04-08 16:20 Europe/Madrid BREAKOUT SESSION | ADVANCES IN POLYMYALGIA VASCULITIS 2024
     
    BREAKOUT SESSION
    ADVANCES IN POLYMYALGIA RHEUMATICA

    Chairs:
    Sebastian Unizony. Mass General Hospital – Harvard Medical School, Boston, USA
    Carlo Salvarani. Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Lecture: Imaging findings in polymyalgia rheumatica
    Online Speaker: Claire Owen. Austin Health, Melbourne, VIC 3081, Australia

    Lecture: Advances in the treatment of Polymyalgia rheumatica
    Speaker: Christian Dejaco. Hospital of Bruneck, Bruneck, Italy

    Lecture: How and when to look for occult giant-cell arteritis in patients with polymyalgia rheumatica
    Speaker: Daniel Blockmans. University Hospitals Leuven, Leuven, Belgium

    MONDAY, 8 APRIL | 15:00-16:20 | ROOM 118 + 119
    Add to calendar 2024-04-08 15:00 2024-04-08 16:20 Europe/Madrid BREAKOUT SESSION | OPTIMIZING NEW TREATMENTS VASCULITIS 2024
     
    BREAKOUT SESSION
    OPTIMIZING NEW TREATMENTS

    Chairs:
    Rachel Jones. Cambridge University Hospitals, Cambridge, United Kingdom
    Charles Pusey. Imperial College London, London, United Kingdom

    O-034. Avacopan for the treatment of ANCA-associated vasculitis: a multicenter prospective, real-life, study on efficacy, safety and impact on quality of life
    Speaker:
    Elena Treppo. University of Udine, Udine, Italy

    O-035. A UK parallel cohort study on renal ANCA-associated vasculitis outcomes for avacopan exposed and matched unexposed cohorts
    Speaker:
    Lucy Frances. Cambridge University Hospital, Cambridge, United Kingdom

    O-036. Avacopan in combination with rituximab and low-dose cyclophosphamide for treatment of severe ANCA-associated glomerulonephritis
    Speaker:
    Amrita Dhutia. Imperial College London, London, United Kingdom

    O-037. Safety and efficacy of avacopan in patients 65 years and older with ANCA-associated vasculitis.
    Speaker:
    Sebastian Sattui. University of Pittsburgh, Pittsburgh, United States.

    O-038. Anti-IL-5 receptor therapy with benralizumab in the management of eosinophilic granulomatosis with polyangiitis (EGPA)
    Speaker:
    Allyson Egan. Vasculitis & Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom

    O-039. Comparative efficacy of mepolizumab 100 mg, mepolizumab 300 mg and benralizumab 30 mg in eosinophilic granulomatosis with polyangiitis
    Speaker:
    Marta Codirenzi. University of Padua, Padua, Italy

    MONDAY, 8 APRIL | 16:40-17:40 | ROOM 112
    Add to calendar 2024-04-08 16:40 2024-04-08 17:40 Europe/Madrid DEBATE | SHOULD GLUCOCORTICOID DISCONTINUATION AS IN CLINICAL TRIALS BE A THERAPEUTIC TARGET IN REAL LIFE? VASCULITIS 2024
     
    DEBATE
    SHOULD GLUCOCORTICOID DISCONTINUATION AS IN CLINICAL TRIALS BE A THERAPEUTIC TARGET IN REAL LIFE?

    Chairs:
    Rona Smith. University of Cambridge, Cambridge, United Kingdom
    Peter Merkel. University of Pennsylvania, Philadelphia, United States

    Viewpoint 1. Speaker: Sebastian Unizony. Mass General Hospital – Harvard Medical School, Boston, USA

    Viewpoint 2. Speaker
    : Benjamin Terrier. Cochin Hospital, Paris, France

    MONDAY, 8 APRIL | 16:40-17:40 | ROOM 113
    Add to calendar 2024-04-08 16:40 2024-04-08 17:40 Europe/Madrid DEBATE | DOES PLASMA EXCHANGE HAVE A ROLE IN ANCA-ASSOCIATED VASCULITIS? VASCULITIS 2024
     
    DEBATE
    DOES PLASMA EXCHANGE HAVE A ROLE IN ANCA-ASSOCIATED VASCULITIS?

    Chairs:
    Marta Casal Moura. Mayo Clinic, Rochester, Minnesota, United States
    David Jayne. University of Cambridge, Cambridge, United Kingdom.

    Viewpoint 1. Speaker: Michael Walsh. McMaster University, Hamilton, Canada

    Viewpoint 2. Speaker
    : Wladimir Szpirt. Copenhagen University Hospital, Copenhagen, Denmark

    MONDAY, 8 APRIL | 16:40-17:40 | ROOM 118 + 119
    Add to calendar 2024-04-08 16:40 2024-04-08 17:40 Europe/Madrid SMALL WORKSHOP | CHOOSING ADJUVANT THERAPY (CONVENTIONAL OR TARGETED) IN TAKAYASU ARTERITIS VASCULITIS 2024
     
    SMALL WORKSHOP
    CHOOSING ADJUVANT THERAPY (CONVENTIONAL OR TARGETED) IN TAKAYASU ARTERITIS

    Leaders:
    Haner Direskeneli. Marmara University, Istanbul, Turkey
    Carol Langford. Cleveland Clinic, Cleveland, United States
    Misra Durga Prasanna. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    MONDAY, 8 APRIL | 17:40-18:40 | ROOM 112
    Add to calendar 2024-04-08 17:40 2024-04-08 18:40 Europe/Madrid CASE REPORT AND PANEL DISCUSSION VASCULITIS 2024
     
    CASE REPORT AND PANEL DISCUSSION

    Panel:
    Elizabeth Brouwer. University Medical Center Groningen, Groningen, The Netherlands
    Roser Solans-Laque. Hospital General Vall d'Hebron, Barcelona, Spain
    Michael Clarkson. Cork University Hospital, Cork, Ireland

    O-040. ANCA associated vasculitis (AAV)-phenotype and ANCA positivity in monogenic lupus secondary to DNASE1L3mutations: report of a case and review of the literature
    Speaker: Giulia Palazzini. University of Firenze, Firenze, Italy

    O-041. When you are told your 34-year old patient with Takayasu’s disease has metastases
    Speaker: Irene Carrión Barberà. Hospital del Mar, Barcelona, Spain

    O-042. A novel role for obinutuzumab in a patient with relapsing PR3 ANCA-associated vasculitis and anti-GBM disease
    Speaker: Tariq Farra. Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

    O-043. Bilateral renal infarcts as a manifestation of Granulomatous Eosinophilic Polyangiitis
    Speaker: Pedro Lisboa-Gonçalves. Centro Hospitalar Universitário São João, Porto, Portugal

    O-044. Acrocyanosis After Immunotherapy: Vasculitis or Vasculopathy? A New Iatrogenic Disease
    Speaker: Jamal Shahin. University of British Columbia, Vancouver, Canada

    MONDAY, 8 APRIL | 17:40-18:40 | ROOM 113
    Add to calendar 2024-04-08 17:40 2024-04-08 18:40 Europe/Madrid DEBATE | SHOULD TOCILIZUMAB BE USED IN EVERY PATIENT WITH GIANT-CELL ARTERITIS? VASCULITIS 2024
     
    DEBATE
    SHOULD TOCILIZUMAB BE USED IN EVERY PATIENT WITH GIANT-CELL ARTERITIS?

    Chairs:
    Maxime Samson. Dijon University Hospital, Dijon, France
    Robert Spiera. Weill Cornell Medicine, New York, United States.
    Carol Langford. Weill Cornell Medicine, New York, United States

    Viewpoint 1. Speaker: Philip Seo. Johns Hopkins University, Baltimore, MD, United States

    Viewpoint 2. Speaker: Bernhard Hellmich. University of Tübingen, Kirchheim-Teck, Germany

    MONDAY, 8 APRIL | 17:40-18:40 | ROOM 118 + 119
    Add to calendar 2024-04-08 17:40 2024-04-08 18:40 Europe/Madrid SMALL WORKSHOP | DIFFERENCES IN GUIDELINES (ACR/EULAR/KDIGO/CANVASC/ JAPANESE) FOR THE TREATMENT OF AAV: IMPLICATIONS FORCLINICAL PRACTICE VASCULITIS 2024
     
    SMALL WORKSHOP
    DIFFERENCES IN GUIDELINES (ACR/EULAR/KDIGO/CANVASC/ JAPANESE) FOR THE TREATMENT OF AAV: IMPLICATIONS FORCLINICAL PRACTICE

    Leaders:
    Marta Casal Moura. Mayo Clinic, Rochester, Minnesota, United States
    Duvuru Geetha. Johns Hopkins University, Baltimore, United States
    Annette Brunchfeld. Linköping University/Karolinska Institutet, Huddinge, Sweden
    Christian Pagnoux. Mount Sinai Hospital, Toronto, Canada
    Toshiko Ito-hara. Kyoto Prefectural University of Medicine, Kyoto, Japan

  • TUESDAY, APRIL 9TH
    Room Plenary room (Room 112) Room 113 Room 118+119 Room 120 Poster Area
    07:00 - 19:00 Registration
    08:00 - 09:45 PLENARY SESSION
    Eosinophilic granulomatosis with polyangiitis and hyperoesinophilic diseases
           
    09:45 - 10:30 COFFEE BREAK POSTER TOUR 3
    10:30 - 12:30 PLENARY SESSION
    Clinically relevant outcomes
           
    12:30 - 13:30   INDUSTRY SYMPOSIUM      
    LUNCH BREAK
    13:30 - 15:00 BREAKOUT SESSION
    Diagnosis and classification of vasculitis
    BREAKOUT SESSION
    Cellular and molecular mechanisms of disease (II)
    BREAKOUT SESSION
    Pediatric vasculitis
       
    15:00 - 16:20 BREAKOUT SESSION
    Advances in treatment (II)
    BREAKOUT SESSION
    Outcome predictors
    BREAKOUT SESSION
    Other forms of vasculitis
       
    16:20 - 16:40 COFFEE BREAK
    16:40 - 17:40 DEBATE
    ANCA negative eosinophilic granulomatosis with polyangiitis (EGPA): a variant of EGPA or closer to the idiopathic hypereosinophilic syndrome
    DEBATE
    Does idiopathic polyarteritis nodosa exist?
    TRAINEE CAREER ORIENTATION SESSION
    Pursuing an academic career in vasculitis
    SMALL WORKSHOP
    Diagnosis, assessment and management of monogenic vasculitis
     
    17:40 - 18:40 CASE REPORT AND PANEL DISCUSSION (II)
    DEBATE
    Biopsy or imaging in the diagnosis of giant-cell arteritis
    TRAINEE SESSION
    3 min presentation of research projects 
    SMALL WORKSHOP
    Predictors of relapse in AAV
     
    TUESDAY, 9 APRIL | 08:00-09:45 | ROOM 112
    Add to calendar 2024-04-09 08:00 2024-04-09 09:45 Europe/Madrid PLENARY SESSION | EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS AND HYPEROESINOPHILIC DISEASES VASCULITIS 2024
     
    PLENARY SESSION
    EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS AND HYPEROESINOPHILIC DISEASES

    Chairs:
    Julia Holle. Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany
    Augusto Vaglio. University of Florence, Firenze, Italy

    Lecture: Advances and translational impact of eosinophil biology
    Speaker: Paneez Khoury. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

    O-045. Benralizumab vs Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis
    Speaker: Michael E. Wechsler. National Jewish Health, Denver, United States

    O-046. Complete Remission in Eosinophilic Granulomatosis with Polyangiitis (EGPA) in the MANDARA Trial of Benralizumab vs Mepolizumab
    Speaker: Michael E. Wechsler. National Jewish Health, Denver, United States

    O-047. Mepolizumab vs Benralizumab: a European real-life retrospective multicentre study
    Speaker: Michelangelo Tesi. Azienda Ospedaliera Universitaria Meyer IRCCS, Firenze, Italy

    O-048. Investigating the impact of Anti-IL5 therapy in eosinophilic granulomatosis with polyangiitis (EGPA); a longitudinal perspective for three years and beyond
    Speaker: Allyson Egan. Vasculitis and Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom

    O-049. Gene expression profile of CD4+ T cells is modified in eosinophilic granulomatosis with polyangiitis (EGPA)
    Speaker: Nuria Farran. IDIBAPS, Hospital Clinic (HC), University of Barcelona (UB), Barcelona, Spain.

    TUESDAY, 9 APRIL | 10:30-12:30 | ROOM 112
    Add to calendar 2024-04-09 10:30 2024-04-09 12:30 Europe/Madrid PLENARY SESSION | CLINICALLY RELEVANT OUTCOMES VASCULITIS 2024
     
    PLENARY SESSION
    CLINICALLY RELEVANT OUTCOMES

    Chairs:
    Luís F Quintana. Hospital Clinic Barcelona, Barcelona, Spain
    Irmgaard Neumann. Vasculitis, Vienna, Austria and Immunologiezentrum Zurich, Switzerland

    O-050. Assessing the predictive role of monitoring creatinine, hematuria, and proteinuria for renal outcomes
    Speaker: Beatriz Sánchez Álamo. Nephrology Department, Hospital Universitario del Sureste, Madrid, Spain

    O-051. Prediction of Recovery of Kidney Function in Severe ANCA Glomerulonephritis.
    Speaker:
    Silke Brix. University Manchester, Manchester, United Kingdom

    O-052. Outcomes after kidney transplantation in anti-Glomerular basement membrane disease
    Speaker:
    Benoit Brilland. CHU Angers, Angers, France

    O-053. Agglomerative hierarchical cluster analysis identifies two clusters of Takayasu arteritis based on clinical phenotype which predict angiographic findings and mortality
    Speaker:
    Misra Durga Prasanna. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    O-054. Outcomes of Intensive Care Patients with Acute Small-Vessel Vasculitis: A 23-year Single-Centre Experience.
    Speaker:
    Arden Dierker Viik. School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

    O-055. Frailty and associated outcomes in patients with vasculitis
    Speaker:
    Sebastian Sattui. University of Pittsburgh, Pittsburgh, United States

    O-056. RETRACE-Clustering Creatinine Trajectory and Baseline Features for Predicting End Stage Kidney Disease
    Speaker:
    Jamsheela Nazeer. Trinity College Dublin, Dublin, India

    O-057. Outcomes after kidney transplantation in ANCA-associated vasculitis
    Speaker:
    Benoit Brilland. CHU Angers, Angers, France

    TUESDAY, 9 APRIL | 09:45-10:30 | POSTER & EXHIBITION AREA
    Add to calendar 2024-04-09 09:45 2024-04-09 10:30 Europe/Madrid COFFEE BREAK & POSTER TOUR 3 VASCULITIS 2024
     
    COFFEE BREAK & POSTER TOUR 3

    3A: ADVANCES IN TREATMENT
    Chair: Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
    • PT-3A-18. Effectiveness of dupilumab on refractory chronic rhinosinusitis with nasal polyps in eosinophilic granulomatosis with polyangiitis: a clinical and cytological study
      Speaker: Federica Davanzo. University of Padua, Padova, Italy
    • PT-3A-19. Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission
      Speaker: Claire Poggi. CH Valenciennes, Valenciennes, France
    • PT-3A-20. Tocilizumab for Polyarteritis Nodosa with cutaneous involvement
      Speaker: Adrien Cottu. Saint-Louis Hospital, Paris, France
    • PT-3A-21. Combination rituximab & low-dose IV cyclophosphamide induction therapy for severe multi-system eosinophilic granulomatosis with polyangiitis
      Speaker: M Srikantharajah. Imperial College London, London, United Kingdom
    • PT-3A-22. Efficacy and drug survival of biologic agents in Behçet’s disease: a real-life observational monocentric study
      Speaker: Eleonora Fiorin. University of Padova, Padova, Italy
    • PT-3A-23. Rituximab in addition to plasma exchange, cyclophosphamide and steroids for treatment of anti-GBM disease
      Speaker: M Srikantharajah. Imperial College London, London, United Kingdom
    • PT-3A-24. De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome
      Speaker: Gulen Hatemi. Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey

    3B: OUTCOMES AND PREDICTORS

    Chair:
    Sara Monti. University of Pavia, Pavia, Italy.
    • PT-3B-49. All-Cause and Cause-Specific Mortality In ANCA-Associated Vasculitis: a Population-based Study
      Speaker: Anna Wilding. Lund University, Lund, Sweden
    • PT-3B-50. Patient-reported sinonasal symptoms and risk of relapse in ANCA-associated vasculitis
      Speaker: Rennie Rhee. University of Pennsylvania, Philadelphia, United States
    • PT-3B-51. The Impact of Chronologic vs Biologic Age on Outcomes in Older Adults with ANCA-Associated Vasculitis
      Speaker: Sebastian Sattui. University of Pittsburgh, Pittsburgh, United States
    • PT-3B-52. Reduced levels of C5a Complement Receptor Antibodies are linked to Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
      Speaker: Sebastian Klapa. University of Lübeck, Lübeck, Germany
    • PT-3B-53. Mortality Rate by Diagnosis in ANCA-Associated Vasculitis Across FAIRVASC Registries
      Speaker: Michelangelo Tesi. Meyer Children's Hospital IRCCS, Firenze, Italy
    • PT-3B-54. Incidence, Prevalence and Mortality of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in England: A Retrospective Cohort Study
      Speaker: Anat Shavit. AstraZeneca, Cambridge, United Kingdom
    • PT-3B-55. Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis using Simulation Modeling
      Speaker: Naomi Patel. MGH, Boston, United States

    3C: BIOMARKERS OF CLINICAL RELEVANCE

    Chair:
    Maria Sandovici. University Medical Center Groningen, Groningen, The Netherlands
    • PT-3C-80. Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
      Speaker: Jaeyun Sung. Mayo Clinic, Rochester, United States
    • PT-3C-81. Gut Dysbiosis with Oral-derived Campylobacter as a Potential Predictor for Aortic Aneurysm Formation and Progression in Takayasu Arteritis
      Speaker: Yoshikazu Nakaoka. National Cerebral and Cardiovascular Center, Suita, Japan
    • PT-3C-82. Association of urinary adhesion molecules derived from endothelial cells and kidney pathology in ANCA-associated glomerulonephritis
      Speaker: Naotake Tsuboi. Fujita Health University, Toyoake, Aichi, Japan
    • PT-3C-83. Discovery and Validation of Novel Circulating Protein Biomarkers in ANCA-Associated Vasculitis
      Speaker: Zachary Wallace. Massachusetts General Hospital, Boston, United States
    • PT-3C-84. Clustering model of 23 antibodies against G protein-coupled receptors (GPCR) identifies two different subsets of ANCA-associated vasculitis (AAV) with different prognoses
      Speaker: Sebastian Klapa. University of Lübeck, Lübeck, Germany
    • PT-3C-85. Identification of kidney transcripts associated with prognosis in ANCA-associated glomerulonephritis
      Speaker: Benoit Brilland. CHU Angers, Angers, France
    • PT-3C-86. Fibrosis and CD-163+ macrophages: making a difference between MPO-AAV and PR3-AAV
      Speaker: Silvia Benito García. Fundació Puigvert, Barcelona, Spain

    TUESDAY, 9 APRIL | 13:30-15:00 | ROOM 112
    Add to calendar 2024-04-09 13:30 2024-04-09 15:00 Europe/Madrid BREAKOUT SESSION | DIAGNOSIS AND CLASSIFICATION OF VASCULITIS VASCULITIS 2024
     
    BREAKOUT SESSION | DIAGNOSIS AND CLASSIFICATION OF VASCULITIS

    Chairs:
    Cristina Ponte. Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
    Ravi Suppiah. Te Whatu Ora - Health New Zealand, Auckland, New Zealand

    O-058. Application of the EULAR/PRINTO/PRES (Ankara 2008) Classification Criteria for IgA Vasculitis in Adults
    Speaker
    : Yagmur Bayindir. Hacettepe University Children’s Hospital, Ankara, Turkey

    O-059. Data driven subclassification of ANCA associated vasculitis – model-based clustering of the FAIRVASC cohort

    Speaker: Karl Gisslander. Lund University, Lund, Sweden

    O-060. Application of the 2022 ACR/EULAR classification criteria in a cohort of 152 patients with microscopic polyangiitis and granulomatosis with polyangiitis.
    Speaker:
    João Fernandes-Serodio. Hospital Fernando Fonseca, Amadora, Portugal

    O-061. Using a standardised biopsy evaluation increases the impact of temporal artery biopsy in GCA
    Speaker: Ömer Karadağ. Turkish Vasculitis Study Group (TRVaS), Ankara, Turkey

    O-062. How giant cell arteritis ultrasound diagnostics may profit from phantom research
    Speaker:
    Haneke Maan. Hospital Group Twente, Almelo, Netherlands

    O-063. Diagnostic performance of short and long [18F]FDG-PET acquisition in giant cell arteritis
    Speaker: Marieke van Niewland. Hospital Group Twente, Almelo, Netherlands

    TUESDAY, 9 APRIL | 13:30-15:00 | ROOM 113
    Add to calendar 2024-04-09 13:30 2024-04-09 15:00 Europe/Madrid BREAKOUT SESSION | CELLULAR AND MOLECULAR MECHANISMS OF DISEASE (II) VASCULITIS 2024
     
    BREAKOUT SESSION
    CELLULAR AND MOLECULAR MECHANISMS OF DISEASE (II)

    Chairs:
    Kazuo Suzuki. Chiba University, Chiba, Japan
    Mark Little. Trinity College Dublin, Dublin, Ireland

    O-064. Lung Granulomas in Murine GPA are Induced by MPO-ANCA and Begin as Microabscesses that Evolve into Granulomas

    Speaker: J. Charles Jennette. UNC Chapel Hill, Chapel Hill, United States

    O-065. Neutrophil proteases and free fatty acids mediate giant cell and granuloma formation in GPA: implications for therapy
    Speakers:
    Alan Salama. Royal Free Hospital And UCL Kidney and Bladder Health, London, United Kingdom

    O-066. Human MPO-ANCA induces crescentic glomerulonephritis in mice expressing human MPO and FcgRIIa
    Speaker:
    Minh Huan Dang. Monash Medical Centre, Clayton, Victoria, Australia

    O-067. The sequential carbonyl derivatives and hydrazones adduct formation on myeloperoxidase contribute to development of auto-antigenicity
    Speaker:
    Gang Xi. University of North Carolina at Chapel Hill, UNC Kidney Center, Chapel Hill, United States

    O-068. Isolation and profiling of auto-antigen specific B cells in MPO-ANCA vasculitis
    Speaker:
    Dhruti Chen. UNC, Chapel Hill, United States

    O-069. Unraveling the impact of TSST-1 on T and B cell response in granulomatosis with polyangiitis: Insights into disease pathogenesis and progression
    Speaker
    : Hang Liao. University Medical Center Groningen, Groningen, Netherlands

    TUESDAY, 9 APRIL | 13:30-15:00 | ROOM 118 + 119
    Add to calendar 2024-04-09 13:30 2024-04-09 15:00 Europe/Madrid BREAKOUT SESSION | PEDIATRIC VASCULITIS VASCULITIS 2024
     
    BREAKOUT SESSION
    PEDIATRIC VASCULITIS

    Chairs:
    Seza Ozen. Hacettepe University, Ankara, Turkey
    Jordi Anton. Hospital maternoinfantil Sant Joan de Deu, Barcelona, Spain

    Lecture: Hypoxia signaling and vasculitis: connecting HIFs with coronary artery damage in Kawasaki disease

    Speaker: Silvia Martin Puig. National Center for Cardiovascular Research, Madrid, Spain

    O-070. ANCA-Associated Vasculitis at Children’s Hospital Colorado: Pediatric Patient Characteristics, Clinical Course, and Outcomes
    Speakers:
    Jessica Bloom. University of Colorado, Denver, United States

    O-071. Clinical course of pediatric-onset Behçet's Disease in young adulthood
    Speaker: Tugce Bozkurt. Marmara University School of Medicine, Istanbul, Turkey

    O-072. HLA class I and II gene polymorphisms in childhood IgA vasculitis
    Speaker
    : Marija Jelusic. University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

    O-073. Kidney transplantation in chilldhood-onset ANCA-associated vasculitis: outcomes of a multicentre cohort
    Speaker: Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

    TUESDAY, 9 APRIL | 15:00-16:20 | ROOM 112
    Add to calendar 2024-04-09 15:00 2024-04-09 16:20 Europe/Madrid BREAKOUT SESSION | ADVANCES IN TREATMENT (II) VASCULITIS 2024
     
    BREAKOUT SESSION
    ADVANCES IN TREATMENT (II)

    Chairs:
    Marten Segelmark. Lund Univeristy, Lund, Sweden
    Montserrat Díaz. Fundació Puigvert, Barcelona, Spain

    O-074. Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with ANCA-Associated Vasculitis with Kidney Involvement Treated with Avacopan
    Speaker:
    Peter A. Merkel. University of Pennsylvania, Philadelphia, United States

    O-075. Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
    Speaker:
    Benjamin Terrier. AP-HP Cochin Hospital, Paris, France

    O-076. Kinetics of auto-antibodies removal with immunoadsorption or plasma exchange: results of the CINEVAS study
    Speaker: Benjamin Terrier. AP-HP Cochin Hospital, Paris, France

    Lecture: Emerging targeted therapies in vasculitis
    Speaker: David Jayne. University of Cambridge, Cambridge, United Kingdom

    TUESDAY, 9 APRIL | 15:00-16:20 | ROOM 113
    Add to calendar 2024-04-09 15:00 2024-04-09 16:20 Europe/Madrid BREAKOUT SESSION | OUTCOME PREDICTORS VASCULITIS 2024
     
    BREAKOUT SESSION
    OUTCOME PREDICTORS

    Chairs:
    Duvuru Geetha. Johns Hopkins University, Baltimore, United States
    Annelies Berden. Maasstad Hospital, Rotterdam, the Netherlands

    O-077. Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis
    Speaker:
    Aglaia Chalkia. University of Cambridge, Department of Medicine, Cambridge, United Kingdom

    O-078. Frequency and the effects of spondylarthritis spectrum disorders on the clinical course and management of Takayasu arteritis
    Speaker:
    Fatma Alibaz-Oner. Marmara University, Istanbul, Turkey

    O-079. ABO blood groups and increased risk for vascular involvement in patients with Behçet disease
    Speaker:
    Erden Bektas. Istanbul University, Istanbul, Turkey

    O-080. Renal prognosis of dialysis-dependent patients at baseline in ANCA-associated vasculitis.
    Speaker:
    Benjamin Terrier. Hôpital Cochin, Paris, France

    O-081. The prognostic value of presenting features on the short and long –term prognosis of giant-cell arteritis patients: data for the Italian Society of Rheumatology group.
    Speaker:
    Alessandro Tomelleri. IRCCS San Raffaele Hospital, Milan, Italy

    TUESDAY, 9 APRIL | 15:00-16:20 | ROOM 118 + 119
    Add to calendar 2024-04-09 15:00 2024-04-09 16:20 Europe/Madrid BREAKOUT SESSION | OTHER FORMS OF VASCULITIS VASCULITIS 2024
     
    BREAKOUT SESSION
    OTHER FORMS OF VASCULITIS

    Chairs:
    Kenneth Warrington. Mayo Clinic, Rochester, United States
    Tanaz Kermani. University of California Los Angeles, Los Angeles, California, United States

    Lecture: Update on IgG4-related disease
    Speaker:
    John H Stone. Harvard Medical School, Boston, Massachusetts, United States

    O-082. Methotrexate as a steroid-sparing agent in chronic periaortitis (idiopathic retroperitoneal fibrosis): a multicentre randomised clinical trial
    Speaker:
    Francesco Peyronel. University of Firenze, Firenze, Italy

    O-083. Histopathological evaluation of IgG4-RD using the 2019 ACR/EULAR scoring system
    Speaker:
    Jet Vedder-Hobbelink. University Medical Center Groninge, Groningen, Netherlands

    O-084. Rituximab in adult-onset IgA Vasculitis and crescentic IgA Nephropathy. A multicentre study
    Speaker:
    Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

    TUESDAY, 9 APRIL | 16:40-17:40 | ROOM 112
    Add to calendar 2024-04-09 16:40 2024-04-09 17:40 Europe/Madrid DEBATE | ANCA NEGATIVE EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A VARIANT OF EGPA OR CLOSER TO THE IDIOPATHIC HYPEREOSINOPHILIC SYNDROME? VASCULITIS 2024
     
    DEBATE
    ANCA NEGATIVE EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A VARIANT OF EGPA OR CLOSER TO THE IDIOPATHIC HYPEREOSINOPHILIC SYNDROME?

    Chairs:
    Julia Holle. Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany
    Allyson Egan. Vasculitis and Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom

    Viewpoint 1. Speaker: Paneez Khoury. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

    Viewpoint 2. Speaker
    : Florence Roufosse. Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

    TUESDAY, 9 APRIL | 16:40-17:40 | ROOM 113
    Add to calendar 2024-04-09 16:40 2024-04-09 17:40 Europe/Madrid DEBATE | DOES IDIOPATHIC POLYARTERITIS NODOSA EXIST? VASCULITIS 2024
     
    DEBATE
    DOES IDIOPATHIC POLYARTERITIS NODOSA EXIST?

    Chairs:
    Xavier Puechal. Hôpital Cochin, Université Paris Cité, Paris, France
    Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

    Viewpoint 1. Speaker: Omer Karadag. Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Viewpoint 2. Speaker
    : Richard Watts. Norwich Medical School, Norwich, United Kingdom

    TUESDAY, 9 APRIL | 16:40-17:40 | ROOM 118 + 119
    Add to calendar 2024-04-09 16:40 2024-04-09 17:40 Europe/Madrid TRAINEE CAREER ORIENTATION SESSION | PURSUING AN ACADEMIC CAREER IN VASCULITIS VASCULITIS 2024
     
    TRAINEE CAREER ORIENTATION SESSION
    PURSUING AN ACADEMIC CAREER IN VASCULITIS

    Chairs:
    Elizabeth Brouwer. University Medical Center Groningen, Groningen, The Netherlands
    Ann Morgan. University of Leeds, Leeds, United Kingdom

    Lecture: The Clinician Scientist Career: Challenges and opportunities
    Speaker: Jatin Vyas. Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

    Panel:
    - Senior Clinician scientist: Alan Salama. University College London, London, United Kingdom
    - Mid-career clinician scientist: Maxime Samson. Dijon University Hospital, Dijon, France
    - Mid-career clinician scientist: Maria Sandovici. University Medical Center Groningen, Groningen, The Netherlands

    TUESDAY, 9 APRIL | 16:40-17:40 | ROOM 120
    Add to calendar 2024-04-09 16:40 2024-04-09 17:40 Europe/Madrid SMALL WORKSHOP | DIAGNOSIS, ASSESSMENT AND MANAGEMENT OF MONOGENIC VASCULITIS VASCULITIS 2024
     
    SMALL WORKSHOP
    DIAGNOSIS, ASSESSMENT AND MANAGEMENT OF MONOGENIC VASCULITIS

    Leaders:
    Seza Ozen. Hacettepe University, Ankara, Turkey
    Peter Grayson. National Institutes of Health, Bethesda, United States
    Juan Ignacio Arostegui. Hospital Clinic Barcelona, Barcelona, Spain

    TUESDAY, 9 APRIL | 17:40-18:40 | ROOM 112
    Add to calendar 2024-04-09 17:40 2024-04-09 18:40 Europe/Madrid CASE REPORT AND PANEL DISCUSSION (II) VASCULITIS 2024
     
    CASE REPORT AND PANEL DISCUSSION (II)

    Panel:
    Allyson Egan. Vasculitis & Lupus Clinic, Cambridge University Hospital, Cambridge, United Kingdom
    Juan Ignacio Arostegui. Hospital Clinic Barcelona, Barcelona, Spain
    Carol Langford. Cleveland Clinic, Cleveland, United States

    O-085. Giant cell arteritis in patients with systemic sclerosis: a case series
    Speaker: Max Guarda. Mayo Clinic, Rochester, MN, United States

    O-086. Managing relapse and progressive multifocal leukoencephalopathy in PR3 ANCA-positive vasculitis: the balance between immunosuppression and immunocompetence.
    Speaker: Giorgio Trivioli. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

    O-087. VEXAS masquerading as Granulomatosis with Polyangiitis (GPA)
    Speaker: Arslan Ather. Peterborough City Hospital, Peterborough, United Kingdom

    O-088. Paraneoplastic MPO+ ANCA vasculitis in Chronic Lymphocytic Leukemia
    Speaker: Katherine Jicha. UNC Kidney Center, Chapel Hill, United States

    O-089. A case of a puerperal granulomatosis with polyangiitis relapse
    Speaker: Cliona Cowhig. Cork University Hospital, Cork, Republic of Ireland

    TUESDAY, 9 APRIL | 17:40-18:40 | ROOM 113
    Add to calendar 2024-04-09 17:40 2024-04-09 18:40 Europe/Madrid DEBATE | BIOPSY OR IMAGING IN THE DIAGNOSIS OF GIANT-CELL ARTERITIS? VASCULITIS 2024
     
    DEBATE
    BIOPSY OR IMAGING IN THE DIAGNOSIS OF GIANT-CELL ARTERITIS?

    Chairs:
    Kenneth Warrington. Mayo Clinic, Rochester, United States
    Eugenio de Miguel. Hospital Universitario La Paz, Madrid, Spain

    Viewpoint 1. Speaker: Wolfgang Schmidt. Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany

    Viewpoint 2. Speaker: Maria C Cid. Hospital Clínic de Barcelona, Barcelona, Spain

    TUESDAY, 9 APRIL | 17:40-18:40 | ROOM 118 + 119
    Add to calendar 2024-04-09 17:40 2024-04-09 18:40 Europe/Madrid TRAINEE SESSION | 3 MIN PRESENTATION OF RESEARCH PROJECTS VASCULITIS 2024
     
    TRAINEE SESSION
    3 MIN PRESENTATION OF RESEARCH PROJECTS

    Panel:
    Neeraj Dhaun. University of Edinburgh, Royal Infirmary of Edinburgh, Centre for Cardiovascular Science, Edinburgh, United Kingdom
    Peter Heeringa. University Medical Center Groningen, Groningen, The Netherlands
    Aladdin Mohammad. Lund University, Lund, Sweden
    Maxime Samson. Dijon University Hospital, Dijon, France

    Leveraging High-Resolution Spatial Transcriptomics to Elucidate Cellular
    Interactions and Complement Pathways in ANCA-Associated Vasculitides
    Speaker: Eléonore Bettacchioli. CHU de Brest, Brest, France

    Combination rituximab & low-dose IV cyclophosphamide induction therapy for severe multi-system eosinophilic granulomatosis with polyangiitis
    Speaker: Mukunthan Srikantharajah. Imperial College London, London, United Kingdom

    Personalisation of relapse risk in autoimmune disease
    Speaker: Angel Mary George. Trinity College, Dublin, Republic of Ireland

    Cytomegalovirus driven renal damage in active ANCA-associated vasculitis (AAV)
    Speaker: Catherine King. University of Birmingham, Edgbaston, United Kingdom

    FAP-PET imaging in giant cell arteritis: discrimination and prediction
    Speaker: Milena Bond. Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy., Brunico, Italy

    Impact of low complement C3 and C4 serum levels at diagnosis in outcomes in ANCA vasculitis patients – a multicenter study
    Speaker: Mariana Diz Lopes. Centro Hospitalar Universitário de São João, Porto, Portugal

    Rituximab vs. Combination of Rituximab and Cyclophosphamide Induction Therapy for ANCA-associated vasculitis: A retrospective study.
    Speaker: Katja Von Allwörden, University of Lübeck, Lübeck, Germany

    TUESDAY, 9 APRIL | 17:40-18:40 | ROOM 120
    Add to calendar 2024-04-09 17:40 2024-04-09 18:40 Europe/Madrid SMALL WORKSHOP | PREDICTORS OF RELAPSE IN AAV VASCULITIS 2024
     
    SMALL WORKSHOP
    PREDICTORS OF RELAPSE IN AAV

    Leaders:
    Mark Little. Trinity College Dublin, Dublin, Ireland
    Irmgard Neumann. Vasculitis, Vienna, Austria and Immunologiezentrum Zurich, Switzerland
    Silke Brix. Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
    Andreas Kronbichler. Medical University Innsbruck, Innsbruck, Austria.

  • WEDNESDAY, APRIL 10TH
    Room Plenary room (Room 112) Room 113 Poster Area
    07:30 - 16:00 Registration
    08:00 - 09:45 PLENARY SESSION
    End-organ damage and repair 
       
    09:45 - 10:30 COFFEE BREAK POSTER TOUR 4
    10:30 - 12:30 PLENARY SESSION
    ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis
       
    12:30 - 13:30 LUNCH BREAK
    13:30 - 15:00 BREAKOUT SESSION
    Imaging in disease assessment
    BREAKOUT SESSION
    Co-morbidities 
     
       
    15:00 - 15:30 CLOSING REMARKS    
    WEDNESDAY, 10 APRIL | 08:00-09:45 | ROOM 112
    Add to calendar 2024-04-10 08:00 2024-04-10 09:45 Europe/Madrid PLENARY SESSION | END-ORGAN DAMAGE AND REPAIR VASCULITIS 2024
     
    PLENARY SESSION
    END-ORGAN DAMAGE AND REPAIR

    Chairs:
    Jacobo Sellares. Hospital Clinic Barcelona, Barcelona, Spain
    Juan C Nieto. National Center for Genomic Analysis (CNAG), Barcelona, Spain

    Lecture: Mechanisms of organ fibrosis.
    Speaker: Robert Lafyatis. University of Pittsburgh, Pittsburgh, Pennsylvania

    O-090. Classical monocyte-derived and SPP1 lipid-associated macrophages orchestrate inflammatory and fibrotic processes in ANCA-associated glomerulonephritis
    Speaker: Yosta Vegting. AmsterdamUMC, Amsterdam, The Netherlands

    O-091. Activated B-cells induce fibroblast activation and cytokine production in giant cell arteritis
    Speaker:
    Shuang Xu. University Medical Center Groningen, Groningen, The Netherlands

    O-092. Long-term Observational Study of Interstitial Lung Disease in ANCA-Associated Vasculitis: European Multicentre Study
    Speaker: Aglaia Chalkia. University of Cambridge, Department of Medicine, Cambridge, United Kingdom

    Lecture: Lung fibrosis in ANCA-associated vasculitis: clinical, imaging and therapeutic perspective
    Speaker: Ulrich Specks. Mayo Clinic Rochester, Rochester, Minnesota, United States

    WEDNESDAY, 10 APRIL | 10:30-12:30 | ROOM 112
    Add to calendar 2024-04-10 10:30 2024-04-10 12:30 Europe/Madrid PLENARY SESSION | ACR-EULAR CRITERIA FOR CLINICAL RESPONSE IN ANCA-ASSOCIATED VASCULITIS VASCULITIS 2024
     
    PLENARY SESSION
    ACR-EULAR CRITERIA FOR CLINICAL RESPONSE IN ANCA-ASSOCIATED VASCULITIS

    Panel:
    Kaitlin A Quinn. National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland
    Sara Monti. University of Pavia, Pavia, Italy
    Gunnar Tomasson. University of Iceland, Reykjavik, Iceland
    Peter Merkel. University of Pennsylvania, Philadelphia, United States

    Introduction and Rationale for Developing Criteria for Response for ANCA-Associated Vasculitis

    Results from the systematic literature review and Delphi exercise

    Methodology and results of data-driven steps to derive the ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis

    The ACR-EULAR Criteria for Clinical Response in ANCA-Associated Vasculitis: Final criteria and use in clinical trials

    Questions and Answers

    WEDNESDAY, 10 APRIL | 13:30-15:00 | ROOM 112
    Add to calendar 2024-04-10 13:30 2024-04-10 15:00 Europe/Madrid BREAKOUT SESSION | IMAGING IN DISEASE ASSESSMENT VASCULITIS 2024
     
    BREAKOUT SESSION
    IMAGING IN DISEASE ASSESSMENT

    Chairs:
    Wolfgang Schmidt. Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany
    Cristina Ponte. Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
    Daniel Blockmans. University Hospitals Leuven, Leuven, Belgium

    Lecture: Emerging radiotracers for vascular imaging
    Speaker: Jason Tarkin. University of Cambridge, Cambridge, United Kingdom

    O-093. Association of extent of vascular inflammation on cranial MRI with visual complications in giant cell arteritis.
    Speaker: Rennie Rhee. University of Pennsylvania, Philadelphia, United Statesç

    O-094. Imaging and clinical predictors of outcomes in chronic periaortitis.
    Speaker: Milena Bond. Hospital of Brunico, Brunico, Italy

    O-095. Predictors of disease relapse in ANCA-associated vasculitis with radiomics of lung nodules/masses.
    Speaker: Samuel Falde. Mayo Clinic, Rochester, United States

    O-096. Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab.
    Speaker: Kaitlin Quinn. NIAMS. National Institutes of Health, Bethesda, United States

    O-097. Comparing Clinical and Imaging assessment in Three Takayasu’s Arteritis Cohorts by using the Takayasu's Arteritis Disease Activity Index
    Speaker: Chiara Marvisi. Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy

    O-098. Protocolised ultrasonography led pathway has a high sensitivity for diagnosis of primary large vessel vasculitis
    Speaker: Chetan Mukhtyar. Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

    WEDNESDAY, 10 APRIL | 13:30-14:30 | ROOM 113
    Add to calendar 2024-04-10 13:30 2024-04-10 14:30 Europe/Madrid BREAKOUT SESSION | CO-MORBIDITIES VASCULITIS 2024
     
    BREAKOUT SESSION
    CO-MORBIDITIES

    Chairs:
    Joanna Robson. UWE Bristol, Bristol, United Kingdom
    Thomas Neumann. Cantonal Hospital, St. Gallen, Switzerland

    O-099. Comprehensive evaluation of long-term cardiovascular comorbidities among patients with AAV
    Speaker: Beatriz Sánchez Álamo. Hospital Universitario del Sureste, Madrid, Spain

    O-100. Prevalence, predictors, and prognosis of serious infections in Takayasu arteritis – a cohort study.
    Speaker: Durga Prasanna Misra. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    O-101. Hypogammaglobulinemia in patients with ANCA-associated vasculitis, treated with Rituximab
    Speaker: Jens Rathmann. Lund University, Rheumatology, Lund, Sweden

    O-102. Hospitalization rates and features of a large multicentric cohort of patients with ANCA-associated vasculitis
    Speaker: Alvise Berti. CISMED - University of Trento, Trento, Italy

    WEDNESDAY, 10 APRIL | 09:45-10:30 | POSTER & EXHIBITION AREA
    Add to calendar 2024-04-10 09:45 2024-04-10 10:30 Europe/Madrid COFFEE BREAK & POSTER TOUR 4 VASCULITIS 2024
     
    COFFEE BREAK & POSTER TOUR 4

    4A: OUTCOMES AND PREDICTORS

    Chair:
    Joanna Robson. UWE Bristol, Bristol, United Kingdom
    • PT-4A-25. A prospective study of complications and sequelae of glucocorticoid therapy in ANCA- associated vasculitis
      Speaker: Paul Scherbacher. Medius Klinik Kirchheim, Kirchheim unter Teck, Germany
    • PT-4A-26. Manifestations and predictors of neurologic involvement in Behçet’s disease: results from a monocentric study
      Speaker: Margarida Lucas Rocha. CHULN, Lisboa, Portugal
    • PT-4A-27. Evolution and clinical implications of cranial and large vessel FDG-PET/CT activity in giant cell arteritis: a five-year cohort study
      Speaker: Anthony Sammel. Prince of Wales Hospital, Sydney, Australia
    • PT-4A-28. Aortic aneurysm/dilatation development in a prospective cohort of patients with biopsy-proven giant-cell arteritis
      Speaker: Javier Marco-Hernández. Vasculitis Research Unit. Hospital Clínic de Barcelona, Barcelona, Spain
    • PT-4A-29. Sleep Disturbances Among Patients with Vasculitis
      Speaker: Lillian Barra. Western University, London, Canada
    • PT-4A-30. The predictive performance of the renal risk score in patients over 65 years of age with renal ANCA-associated vasculitis
      Speaker: Quentin De Berny. Amiens University Hospital, Amiens, France
    • PT-4A-31. Magnetic resonance imaging reflects disease activity in the “giant cell arteritis treatment with ultra-short glucocorticoids and tocilizumab” trial: the gusto trial
      Speaker: Thomas Daikeler. University of Basel, Basel, Switzerland

    4B: MECHANISMS OF DISEASE
    Chair: Adrian Schreiber. Charité - Universitätsmedizin, Berlin, Berlin, Germany
    • PT-4B-56. Molecular and Immune Pathways in ANCA-associated Glomerulonephritis
      Speaker: Salem Almaani. The Ohio State University, Columbus, United States
    • PT-4B-57.  Drug exposure and subsequent diagnosis with ANCA-associated vasculitis – A population-based case-control study
      Speaker: Burak İ̇nc. Lund University, Lund, Sweden
    • PT-4B-58. The Relationship Between the Netosis Findings and Disease Activity in Behçet Disease
      Speaker: Erdem Bektas. Istanbul University, Istanbul , Turkey
    • PT-4B-59. Hyperhomocysteinemia in Takayasu arteritis - genetically defined or burden of the proinflammatory state?
      Speaker: Eduarda Bonelli Zarur. Universidade Federal de São Paulo - UNIFESP, São Paulo, Brazil
    • PT-4B-60. Induced pluripotent stem derived neutrophils from patients with ANCA vasculitis recapitulate genetic influence on PRTN3 gene expression
      Speaker: Dominic Ciavatta. University of North Carolina at Chapel Hill, Chapel Hill, United States
    • PT-4B-61. Transcriptomic and proteomic impact of blocking GM-CSF receptor with mavrilimumab versus blocking IL-6 receptor with tocilizumab on ex vivo-cultured arteries from patients with GCA
      Speaker: Marc Corbera Bellalta. Hospital Clínic. University of Barcelona. IDIBAPS., Barcelona, Spain
    • PT-4B-62. Interleukin-6(IL-6)/IL-6 receptor and persistence of inflammation in Giant Cell Arteritis. Effects of IL-6 receptor blockade with tocilizumab
      Speaker: Farah Kamberovic. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), BARCELONA, Spain

    4C: DIAGNOSIS AND CLASSIFICATION
    Chair:
    Peter Grayson. National Institutes of Health, Bethesda, United States
    • PT-4C-87. Superb microvascular imaging and high frequency ultrasound for vessel wall evaluation in giant cell arteritis
      Speaker: Christina Svensson. Linköping University, Linköping, Sweden
    • PT-4C-88. Optic nerve sheath enhancement on orbital MRI in giant cell arteritis versus non-arteritic anterior ischemic optic neuropathy
      Speaker: Rennie Rhee. University of Pennsylvania, Philadelphia, United States
    • PT-4C-89. Validating the 2022 ACR/EULAR ANCA-associated vasculitis Classification Criteria in a Japanese Cohort Study; the Japan Collaborative registry of ANca-associated VASculitis (J-CANVAS)
      Speaker: Mabuchi Nakako. University of Yamanashi Hospital, Yamanashi, Japan
    • PT-4C-90. Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts
      Speaker: Shubhasree Banerjee. University of Pennsylvania, Pennsylvania, United States
    • PT-4C-91. HLA-B*51 and its subtypes as diagnostic tools for Behçet’s Disease – where do we stand?
      Speaker: Erika Biegelmeyer. UNIFESP-EPM, São Paulo, Brazil
    • PT-4C-92. The role of miRNAs in classifying ANCA-associated vasculitis: epigenetics versus serology.
      Speaker: Matic Bošnjak. University of Ljubljana, Ljubljana, Slovenia
    • PT-4C-93. Evaluation of the 2022 ACR/EULAR Classification Criteria for GPA and MPA in a European Cohort
      Speaker: Thomas Neumann. Cantonal Hospital St. Gallen , St. Gallen, Switzerland

TECHNICAL SECRETARIAT

C/ Marià Cubí, 4 - Pral | 08006 Barcelona
Tel. +34 932.388.777 | Fax: +34 932.387.488
This email address is being protected from spambots. You need JavaScript enabled to view it.

REGISTRATION

This email address is being protected from spambots. You need JavaScript enabled to view it.

ORGANIZED BY

079600e51becb8a248f111a209631dbd20798ded

  • Last Update: Tuesday 30 April 2024, 08:08:05.